Roche’s Perjeta regimen gets FDA priority review in breast cancer
ZURICH (Reuters) – The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday. The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement. A […]
Read More